1	TITLE PAGE
2	
3	Significant rise of <i>Chlamydia pneumoniae</i> diagnoses at Marseille University Hospitals.
4	2024. France
5	
6	Running title: Dramatic rise of <i>Chlamydia pneumoniae</i> diagnoses
7	
8	Authors list: Sophie Edouard ^{1,2,3 *} , Rayane Attamna ^{1,2} , Matthieu Million ^{1,2,4} , Céline
9	Boschi ^{1,2,4} , Jeremy Delerce ^{1,3} , Aurélia Caputo ^{1,3} , Didier Stoupan ^{1,2} , Seydina Diene ^{1,4} , Idir
10	Kacel ^{1,3} , Claudia Andrieu ^{1,2} , Anthony Levasseur ^{1,3} , Hervé Chaudet ^{1,2,3,5} , Jean-Marc
11	Rolain ^{1,2,4} , Lucile Lesage ⁶ , Aurélie Morand ^{6,7,8} , Pierre-Edouard Fournier ^{1,2,3} , Jean-Christophe
12	Lagier ^{1,2,4} , Florence Fenollar ^{1,2,3} , Bernard La Scola ^{1,2,4} , Philippe Colson ^{1,2,4} *
13	Affiliations: ¹ IHU Méditerranée Infection, Marseille, France; ² AP-HM, Marseille, France;
14	³ Aix Marseille Univ, RITMES, Marseille, France; ⁴ Aix Marseille Univ, MEPHI, Marseille,
15	France; ⁵ CESPA, Marseille, France; ⁶ Service d'accueil des Urgences Pédiatriques, hôpital
16	Timone, AP-HM, 264 rue Saint-Pierre, 13005 Marseille, France; ⁷ AP-HM, service de
17	Pédiatrie générale, Marseille, France; ⁸ AP-HM, hôpital Nord, service d'accueil des Urgences
18	Pédiatriques, Marseille, France.
19	*Corresponding authors: Sophie Edouard (Orcid no. 0000-0002-7294-0558) and Philippe
20	Colson (Orcid no. 0000-0001-6285-0308), IHU Méditerranée Infection, 19-21 boulevard Jean
21	Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:
22	sophie.edouard@ap-hm.fr; philippe.colson@ap-hm.fr
23	
24	Word counts: abstract: 50; main text: 1,197 words

Figures: 2; Table: 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

26 Appendices: Supplementary Methods; Supplementary Results; Supplementary Figure: 1;

27 Supplementary Table: 1

2	a
2	9

SUMMARY

30	We report a 19-fold increase in 2024 of qPCR diagnoses of Chlamydia pneumoniae
31	infections in Marseille, Southern France, with 37 cases versus 10 between 2018-2023. These
32	mostly affected children, and young adults. We obtained four C. pneumoniae genomes, all of
33	serotype ST16, suggesting an epidemic circulation in our geographical area.
34	
35	Keywords: Chlamydia pneumoniae; outbreak; respiratory infections, qPCR; genome
36	
37	MAIN TEXT
38	Respiratory infections are a major cause of morbidity and mortality worldwide
39	regardless of the geographic area. The SARS-CoV-2 pandemic profoundly changed the
40	epidemiology of respiratory infections. This was the case in France, including in Marseille,
41	Southeastern France, with a quasi-absence of influenza diagnoses during winter 2020-2021 or
42	a shift of several months of the epidemic period of respiratory syncytial virus (RSV) in 2021
43	(1,2). In addition, such changes in the incidence of infections were also observed for
44	microorganisms including some involved in respiratory diseases (3).
45	Recently, dramatic increases in the incidence of respiratory microbial infections, due
46	to Mycoplasma pneumoniae (4) then Bordetella pertussis (5) have been observed in France in
47	2023-2024. C. pneumoniae is another bacterium associated with acute respiratory infections
48	and causing from upper respiratory tract mild disease to pneumonia. It is implicated in $<1.5\%$
49	of cases of community-acquired respiratory infections and particularly affects children (6). It
50	usually causes asymptomatic or mild infections but severe cases, asthma exacerbation and
51	chronic respiratory illness can occur (7). Its diagnosis relies mainly on real-time PCR (qPCR).
52	Here we describe a significant recent increase in qPCR diagnoses of C. pneumoniae

respiratory infections, and the epidemiological, microbiological, and genomic characteristicsof these infections.

55

56 The study

We detected in October 2024 an abnormally high number of C. pneumoniae 57 diagnoses. This rise triggered the implementation of an automatic daily report transmissible to 58 59 hospital biologists and clinicians through a basic mailing list and a configurable subscription. We retrospectively analyzed C. pneumoniae qPCR results performed in the clinical 60 microbiology diagnosis laboratory of university/public hospitals of Marseille, Southern 61 62 France, on respiratory samples collected from patients between 01-Jan-2018 and 30-Oct-2024. qPCR was either part from a multiplex syndromic panel (Biofire FilmArray Respiratory 63 panel 2, bioMérieux, Marcy-l'Etoile, France) used at point-of-care laboratories or was an in-64 65 house simplex assay targeting the *omp2* gene (8) (see more detailed procedures in Appendix Methods). Co-infection with other respiratory pathogens was assessed using results of the 66 67 Biofire assay or of the Fast Track Diagnosis Respiratory pathogens 21 assay (Fast Track Diagnosis, Luxembourg). Next-generation sequencing (NGS) was performed on residues of 68 five samples with the lowest known qPCR cycle threshold values (Ct) using Oxford Nanopore 69 70 (Oxford Nanopore Technologies, Oxford, UK) and Illumina technologies (Illumina Inc., San 71 Diego, California, USA), on GridION, and MiSeq and NovaSeq 6000 instruments, respectively. Bioinformatic analyses of NGS reads and phylogenomic analyses were 72 performed as detailed in Appendix Methods. OpenEpi version 3.01 73 (https://www.openepi.com/) was used for statistical analyses (*p*-values ≤ 0.05 were considered 74 significant). 75 Overall, 35,344 specimens collected from patients between 01-Jan-2018 and 30-Oct-76

2024 had been tested, including 30,848 upper and 4,496 lower respiratory samples. Among

78	them, 19,504 samples were collected in men (55%). Median age of patients was 5-year-old
79	(range, 0-107). Overall incidence of C. pneumoniae qPCR-positivity was 0.13% (47/35,344
80	being positive). During 2018-2022, the number of samples tested for C. pneumoniae by qPCR
81	regularly increased, with a peak at 11,754 samples in 2022 (Figure 1a). However, only five
82	samples were positive during this time lapse. In 2023, Biofire assay use was restricted, which
83	was associated with a drop of the total number of C. pneumoniae qPCR tests to 4,294 and
84	5,795 samples in 2023 and 2024, respectively. Nonetheless, in 2024, 37 patients (0.64%) were
85	diagnosed compared to 5 (0.12%) in 2023 (p<0.0001). Five cases occurred between January-
86	June, then six in July-August, 15 in September, and 6 in October 2024 (Figure 1b).
87	The 37 specimens positive in 2024 included 22 nasopharyngeal swabs, 11
88	nasopharyngeal aspirates and 4 sputums. Twenty-eight (76%) were initially diagnosed
89	positive using the Biofire assay. None of the 4,496 low respiratory samples tested positive.
90	Among the 37 patients, 19 (51%) were male; median age was 10-year-old (range, 0-44).
91	Twenty-seven (73%) patients were children <18-year-old and 10 (27%) were young adults.
92	Median age was 8 years (range, 2 months-15 years) in children and 34 (25-44) in adults.
93	Children <1 year, 6-10 years and 11-15 years were the age groups the most represented
94	among C. pneumoniae cases, comprising each between 19-22% of these cases (Table 1). No
95	patient >50 years was diagnosed in 2024. Thirteen patients were admitted in hospitalization,
96	including six for other reasons than severity of respiratory symptoms; no case was admitted in
97	intensive care unit or died. Fourteen (38%) of the 37 patients were coinfected with ≥ 1 other
98	respiratory pathogen, including rhinovirus (n=9), SARS-CoV-2 (n=2), parainfluenza virus
99	(n=1), coronavirus-NL63 (n=1), adenovirus (n=1), coronavirus-HKU1 (n=1), and Bordetella
100	pertussis (n=1) (Figure 2).
101	Two C. pneumoniae whole circular genomes (1,231,868 and 1,232,097 base pair (bp)-

102 longs, in one scaffold) (GenBank Accession no. CP172581 and CP173416), two additional

near full-length genomes in 11 or 12 scaffolds (1,229,923 and 1,231,291 bp-longs) and one 103 104 partial genome in 65 scaffold (306,688 bp) were obtained by NGS directly from respiratory samples (Appendices Results and Table 1). All four (near) full-length genomes were 105 106 classified as ST16 based on MultiLocus Sequencing Typing (Appendices Methods, Table 2), suggesting the circulation of a single serotype in 2024. Only 19 other C. pneumoniae genomes 107 108 were available from GenBank (https://www.ncbi.nlm.nih.gov/genbank/), six being classified 109 as ST16. Phylogenomics indicated that the two full-length genomes obtained here were those the most closely related with each other (Appendices Figures 1a,b). 110

111

112 Conclusion

Global systematic surveillance of diagnoses at our institution allowed detecting a C. 113 pneumoniae ST16 outbreak in 2024 in Marseille, France, which peaked in September. As 114 previously described for *M. pneumoniae* then *B. pertussis* (4,5), we observed that *C.* 115 pneumoniae qPCR positivity rate raised to a level never seen before in our center. Most cases 116 117 affected children and no severe case was reported. As commonly observed in other respiratory 118 infections, we found a high rate of coinfection of *C. pneumoniae* with other pathogens (2,4,6). A resurgence of several respiratory pathogens was observed following the global 119 120 attenuation of the SARS-CoV-2 pandemic (1,3,4-6). Increase of positive C. pneumoniae qPCR cases after the SARS-CoV-2 pandemic was previously observed in 2023 in Switzerland 121 (6); no genome sequencing was reported. C. pneumoniae epidemics were also described 122 before the SARS-CoV-2 pandemic, such as in a prison in Texas in 2014 (9) and among 123 children hospitalized with community-acquired pneumonia in Korea in 2016 (10). 124 The number of *C. pneumoniae* cases is likely underestimated in our study, particularly 125 because patients with mild symptoms are not systematically tested and C. pneumoniae is not 126 part of the respiratory syndromic qPCR panel used at our core laboratory. Indeed, samples 127

128	from \approx 2,000 patients presenting respiratory diseases and requiring routine diagnostic testing
129	between July-October 2024 were not specifically tested for C. pneumoniae. Moreover, the
130	amount of asymptomatic cases that may play a role in the epidemic is unknown. Here, we did
131	not consider C. pneumoniae serological results due to the lower sensitivity and specificity of
132	serology compared to qPCR and to serum unavailability for most case-patients.
133	Unexpectedly, the number of other C. pneumoniae genomes released in GenBank was
134	very few, considering the frequency and pathogenicity of this bacterium, and the sharp
135	interest of microbial genomic surveillance for epidemiology and clinics. Among the 19
136	previously available C. pneumoniae genomes, the most frequent genotype was ST17 (n=11)
137	followed by ST16 (n=6).
138	Overall, present data warrants surveying closely diagnoses of C. pneumoniae
139	infections at the local and country scales; and implementing genomic surveillance and
140	characterizing drug resistance for diagnosed cases.
141	
142	
143	First author's short biographical sketch
144	Dr. Sophie Edouard is a medical bacteriologist at the Microbiological Laboratory at IHU
145	Méditerranée Infection in Marseille, France. Her research interests focus on infectious
146	diseases and microbiology including intracellular bacteria and emerging pathogens.
147	
148	Acknowledgements
149	We are very grateful to the technical team of the next-generation sequencing platform of the
150	IHU Méditerranée Infection.
151	Data availability

- 152 *Chlamydia pneumoniae* genomes in one scaffold analyzed here have been submitted to the
- 153 GenBank sequence database (https://www.ncbi.nlm.nih.gov/genbank/) (11) (GenBank
- 154 Accession no: CP172581 and CP173416).

155 Author contributions

- 156 Conceived and designed the experiments: SE, PC. Contributed materials, analysis tools: All
- authors. Analyzed the data: SE, JD, AC, SD, PC. Writing—original draft preparation: SE, PC.
- 158 Writing—review and editing: All authors. All authors have read and agreed to the published
- 159 version of the manuscript.

160 **Conflicts of interest**

- 161 Authors have no conflicts of interest to declare. Funding sources had no role in the study
- design and conduct, in the collection, management, analysis, and interpretation of the data, or
- 163 in the preparation, review, or approval of the manuscript.

164 Funding

- 165 This work was supported by the French Government under the "Investments for the Future"
- 166 programme managed by the National Agency for Research (ANR), Méditerranée Infection
- 167 10-IAHU-03 and by the French Ministry of Higher Education, Research and Innovation and
- 168 the French Ministry of Solidarity and Health.

169 Ethics

- 170 The present study involves data that have been registered on the Health Data Access Portal of
- 171 Marseille university and public hospitals (Assistance Publique-Hôpitaux de Marseille (AP-
- 172 HM)) under No. PADS24-337, and was approved by the AP-HM Ethics and Scientific

173 Committee.

174

175

176 **References**

- 177 1. Giraud-Gatineau A, Kaba L, Boschi C, Devaux C, Casalta JP, Gautret P, Chaudet H,
- 178 Colson P, Raoult D. Control of common viral epidemics but not of SARS-CoV-2
- through the application of hygiene and distancing measures. J Clin Virol. 2022;150-
- 180 151:105163. doi: 10.1016/j.jcv.2022.105163.
- 181 2. Mantelli C, Colson P, Lesage L, Stoupan D, Chaudet H, Morand A, La Scola B, Boschi
- 182 C. Coinfections and iterative detection of respiratory viruses among 17,689 patients
- between March 2021 and December 2022 in Southern France. J Clin Virol.
- 184 2024;175:105744. doi: 10.1016/j.jcv.2024.105744.
- 185 3. Kaba L, Giraud-Gatineau A, Jimeno MT, Rolain JM, Colson P, Raoult D, et al.
- 186 Consequences of the COVID-19 Outbreak Lockdown on Non-Viral Infectious Agents
- as Reported by a Laboratory-Based Surveillance System at the IHU Méditerranée
- 188 Infection, Marseille, France. J Clin Med. 2021;10(15):3210. doi: 10.3390/jcm10153210.
- 189 4. Edouard S, Boughammoura H, Colson P, La Scola B, Fournier PE, Fenollar F. Large-
- 190 Scale Outbreak of Mycoplasma pneumoniae Infection, Marseille, France, 2023-2024.

191 Emerg Infect Dis. 2024;30(7):1481-4. doi: 10.3201/eid3007.240315.

- 192 5. Rodrigues C, Bouchez V, Soares A, Trombert-Paolantoni S, Aït El Belghiti F, Cohen
- 193 JF, et al. Resurgence of Bordetella pertussis, including one macrolide-resistant isolate,
- 194 France, 2024. Euro Surveill. 2024;29(31):2400459. doi: 10.2807/1560-
- 195 7917.ES.2024.29.31.2400459.
- 196 6. Tagini F, Opota O, Greub G. Chlamydia pneumoniae Upsurge at Tertiary Hospital,
- 197 Lausanne, Switzerland. Emerg Infect Dis. 2024;30(4):810-2. doi:
- 198 10.3201/eid3004.231610.
- Hammerschlag MR, Kohlhoff SA, Gaydos CA. Chlamydia pneumoniae. In Mand
 Douglas Bennetts Princ Pract Infect Dis., 2014;2174; Eds Livingstone.

201 0. WOTELAS, DUDOUIG O, FILDERILE, EDOUALUS, OOUTIELF, CASALAJF, FEL

- 202 Fournier PE, Drancourt M, Raoult D. Complementarity between targeted real-time
- specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven
- diagnosis of infectious diseases. Eur J Clin Microbiol Infect Dis. 2015;34(3):561-70.
- 205 doi: 10.1007/s10096-014-2263-z.
- 206 9. Conklin L, Adjemian J, Loo J, Mandal S, Davis C, Parks S, Parsons T, McDonough B,
- 207 Partida J, Thurman K, Diaz MH, Benitez A, Pondo T, Whitney CG, Winchell JM,
- 208 Kendig N, Van Beneden C. Investigation of a Chlamydia pneumoniae outbreak in a
- Federal correctional facility in Texas. Clin Infect Dis. 2013;57(5):639-47. doi:
- 210 10.1093/cid/cit357.
- 10 Han HY, Moon JU, Rhim JW, Kang HM, Lee SJ, Yang EA. Surge of Chlamydia
- 212 pneumoniae pneumonia in children hospitalized with community-acquired pneumonia
- at a single center in Korea in 2016. J Infect Chemother. 2023;29(5):453-7. doi:
- 214 10.1016/j.jiac.2023.01.012.
- 215 11. Sayers EW, Cavanaugh M, Frisse L, Pruitt KD, Schneider VA, Underwood BA, Yankie
- L, Karsch-Mizrachi I. GenBank 2025 update. Nucleic Acids Res. 2024;gkae1114. doi:

217 10.1093/nar/gkae1114.

218

220	FIGURES
221	
222	Figure 1. Number of respiratory samples tested and positive by a Chlamydia pneumonia
223	qPCR assay between 2018 and 2024 (a) and during Year 2024 (b)
224	
225	Figure 2. Number of coinfections with other infectious agents for respiratory samples positive
226	by a Chlamydia pneumoniae qPCR assay in 2024
227	
228	





b.



TABLES

Table 1. Demographics characteristics and coinfections of the cases of C. pneumoniae

infection diagnosed by qPCR in our center in 2024

Characteristics	n (%)
Incidence of C. pneumoniae cases	37/5795 (0.6)
C. pneumoniae cases	
Male	19/37 (51.4)
Female	18/37 (48.6)
Median age (years)	10
Age distribution (years)	
<1	7/37 (18.9)
1-5	4/37 (10.8)
6-10	8/37 (21.6)
11-15	8/37 (21.6)
16-20	0/37 (0.0)
21-35	6/37 (16.2)
36-50	4/37 (10.8)
> 50	0/37 (0.0)
Number of coinfection	14/37 (37.8)
Incidence of C. pneumoniae infections by age	
groups	
<1	7/11,215 (0.1)
1-5	4/7,074 (0.1)
6-10	8/1,669 (0.5)
11-15	8/1,075 (0.7)
16-20	0/606 (0.0)
21-35	6/1,943(0.3)
36-50	4/2,063 (0.2)
> 50	0/9,698 (0.0)

1	APPENDICES
2	for
3	Significant rise of Chlamydia pneumoniae diagnoses at Marseille University Hospitals,
4	2024, France
5	Authors list: Sophie Edouard ^{1,2,3 *} , Rayane Attamna ^{1,2} , Matthieu Million ^{1,2,4} , Céline
6	Boschi ^{1,2,4} , Jeremy Delerce ^{1,3} , Aurélia Caputo ^{1,3} , Didier Stoupan ^{1,2} , Seydina Diene ^{1,4} , Idir
7	Kacel ^{1,3} , Claudia Andrieu ^{1,2} , Anthony Levasseur ^{1,3} , Hervé Chaudet ^{1,2,3,5} , Jean-Marc
8	Rolain ^{1,2,4} , Lucile Lesage ⁶ , Aurélie Morand ^{6,7,8} , Pierre-Edouard Fournier ^{1,2,3} , Jean-Christophe
9	Lagier ^{1,2,4} , Florence Fenollar ^{1,2,3} , Bernard La Scola ^{1,2,4} , Philippe Colson ^{1,2,4} *
10	Affiliations: ¹ IHU Méditerranée Infection, Marseille, France; ² AP-HM, Marseille, France;
11	³ Aix Marseille Univ, RITMES, Marseille, France; ⁴ Aix Marseille Univ, MEPHI, Marseille,
12	France; ⁵ CESPA, Marseille, France; ⁶ Service d'accueil des Urgences Pédiatriques, hôpital
13	Timone, AP-HM, 264 rue Saint-Pierre, 13005 Marseille, France; ⁷ AP-HM, service de
14	Pédiatrie générale, Marseille, France; ⁸ AP-HM, hôpital Nord, service d'accueil des Urgences
15	Pédiatriques, Marseille, France.
16	*Corresponding authors: Sophie Edouard (Orcid no. 0000-0002-7294-0558) and Philippe
17	Colson (Orcid no. 0000-0001-6285-0308), IHU Méditerranée Infection, 19-21 boulevard Jean
18	Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:
19	sophie.edouard@ap-hm.fr; philippe.colson@ap-hm.fr
20	
21	
22	APPENDIX, SUPPLEMENTARY METHODS
23	qPCR was either part from a multiplex syndromic panel (Biofire FilmArray
24	Respiratory panel 2; bioMérieux, Marcy-l'Etoile, France) used at point-of-care laboratories

operating 24/24 7/7 for urgent requests, or was an in-house simplex qPCR assay targeting the 25

omp2 gene used at the core laboratory operating only on working days (1). Co-infections with 26 27 other respiratory pathogens were assessed using results of the Biofire FilmArray assay, or of the Fast Track Diagnosis Respiratory pathogens 21 assay (Fast Track Diagnosis, 28 29 Luxembourg) performed at the core laboratory on working days. Next-generation sequencing (NGS) was performed at the IHU Méditerranée Infection 30 clinical microbiology and virology laboratory on residues of samples with the lowest qPCR 31 32 cycle threshold values (Ct) using (i) Oxford Nanopore technology with the Ligation Sequencing Kit (SQK-LSK109) and a SpotON flow cell Mk I, R9.4.1 on a GridION 33 instrument (Oxford Nanopore Technologies, Oxford, UK); and (ii) Illumina technology using 34 35 the classic Illumina loading procedure in XP mode on a MiSeq and a NovaSeq 6000 instruments (Illumina Inc., San Diego, California, USA), with a reading of 2x250 and 2x150, 36 37 respectively. 38 Nanopore reads were filtered with filtlong (v0.2.1) (https://github.com/rrwick/Filtlong) while Illumina reads were filtered using fastp (v0.23.4) (2). Only the minimum read length 39 40 parameter was modified, to 1,000 bp for the Nanopore runs, and to 100 base pairs (bp) for the 41 Illumina runs. Cleaned reads were then classified with Kraken2 (v2.0.9-beta) (https://github.com/DerrickWood/kraken2) (3) using the "standard" database from 2024-05-42 43 06, with a confidence threshold of 0.02. Hits corresponding to taxon 83558 (including its offspring) were extracted using KrakenTools (v1.2) 44 (https://github.com/jenniferlu717/KrakenTools) (4). Reads corresponding to Chlamydia spp. 45 were assembled using Unicycler (v0.5.1) (https://github.com/rrwick/Unicycler) (5), Raven 46 (https://github.com/lbcb-sci/raven) (6), and Polypolish (https://github.com/rrwick/Polypolish) 47 48 (7). The resulting genomes were annotated with Bakta (v1.9.4)(https://github.com/oschwengers/bakta) (8) using the "5.1 full" database, and Roary 49 (https://sanger-pathogens.github.io/Roary/) (9). Pangenomic analysis was performed with 50

51 PIRATE (v1.0.5) (https://github.com/SionBayliss/PIRATE) (10) using the -a option to 52 generate the core alignment. The core genome phylogeny was inferred using IQ-TREE2 (http://www.iqtree.org/) (11) with the -m GTR+R option. The pangenome was visualized with 53 Phandango (https://github.com/jameshadfield/phandango) (12), and the phylogenetic tree, 54 including bootstrap values, was annotated with iTOL (https://itol.embl.de/) (13). The 55 MultiLocus Sequencing Typing (MLST) analysis was performed using the PubMLST web 56 57 application (https://pubmlst.org/software/bigsdb) (14) and its database for *Chlamydia* spp. C. pneumoniae genomes were automatically annotated by the NCBI prokaryotic genome 58 annotation pipeline (15). Resistance genes were searched using the Arg-Annot tool (16). 59

60

61 APPENDIX, SUPPLEMENTARY RESULTS

The abnormally high number of C. pneumoniae diagnoses was detected in October 62 63 2024 in our institute. This was discussed during our daily diagnoses report meetings that involve all medical biologists and medical biology residents of the clinical microbiology and 64 65 virology laboratory of Marseille university hospitals at IHU Méditerranée Infection, and during our weekly meetings on epidemiological surveillance of infections based on the data of 66 this laboratory, to which attend medical biologists and clinicians from our infectious diseases 67 68 institute (17). Specific daily automated surveillance of new diagnoses of C. pneumoniae that included the localization in clinical wards of hospitalized cases was newly implemented in 69 October 2024, and transmitted each day to medical biologists and clinicians from Marseille 70 university hospitals, and the rise in the C. pneumoniae diagnoses was reported to the regional 71 72 health agency.

Cycle threshold values (Ct) of our in-house qPCR were available for 28 of the 37 *C*. *pneumoniae*-positive samples and ranged between 18 and 37. The overall incidence of *C*. *pneumoniae* cases was higher in children between 11-15 years (8/1,075, 0.7%) and in children

between 6-10 years (8/1,669, 0.5%), compared to the other age groups (Main text Table 1).
Children <1 year were more frequently coinfected (86%) with ≥1 other respiratory pathogen
compared to the other age groups (Main text Table 1).

79 *C. pneumoniae* genomes were obtained by NGS performed directly from respiratory samples with Ct lower than or or equal to 22 (range, 18-22). The two whole genomes in a 80 single scaffold were obtained from samples with a qPCR Ct of 21. They harbored between 81 82 1,098 and 1,101 genes. Genes encoding hypothetical proteins and DUF-domain containing proteins were those the most frequent, in between 210 and 217 and 64 and 65 cases, 83 respectively. All five genomes obtained here belonged to ST16 based on MultiLocus 84 85 Sequencing Typing (Appendix Table 2), suggesting the circulation of a single serotype during this 2024 outbreak. Only 19 other C. pneumoniae were available Phylogenomic analyses 86 based on mutations in core genes and conducted for the four (near) full-length C. pneumoniae 87 88 genomes (in between 1-12 scaffolds) obtained here and the 19 C. pneumoniae genomes previously released in the GenBank NCBI nucleotide sequence database 89 (https://www.ncbi.nlm.nih.gov/genbank/) (18) indicated that the four (near) full-length 90 91 genomes obtained in our laboratory comprised a cluster, being those the most closely related with each other (Appendices Figures 1a,b). Only 16 mutations differentiated the two whole C. 92 93 *pneumoniae* genomes in a single scaffold obtained here based on the alignment of core genes. Six other genomes from GenBank were classified as of ST16, the most frequent serotype 94 being ST17 (n=11). Resistance gene search revealed the presence of a gene encoding an UDP-95 N-acetylglucosamine 1-carboxyvinyltransferase (murA) potentially associated with 96 fosfomycine resistance, which was only described to our knowledge in Chlamydia 97 trachomatis genomes among Chlamydia spp. (19), and was shared by the other C. 98 pneumoniae genomes. No fluoroquinolone, macrolide or tetracycline resistance genes were 99 found. 100

101 **APPENDIX, SUPPLEMENTARY FIGURES**

- 102
- Appendix, Figure 1. Pangenome analysis showing the cladogram built based on mutations in 103
- core genes for *C. pneumoniae* genomes with (a) or without (b) the representation of genes 104
- b: genes are represented by blue vertical lines. 105
- The four (near) full-length (in 1-12 scaffolds) genomes obtained here are indicated by a red 106
- 107 cross.







110 **APPENDIX, SUPPLEMENTARY TABLES**

- 111
- **Table 1.** Results of the MultiLocus Sequencing Typing (MLST) analysis
 112
- The MLST analysis was performed using the PubMLST (https://pubmlst.org/software/bigsdb) 113
- 114 web application
- 115

		Markers						
Chlamydia pneumoniae genomes	MLST serotype	gatA	oppA	hflX	gidA	enoA	hemN	fumC
Reference genomes for the MLST	ST16	4	7	5	6	5	3	4
	ST17	4	7	5	7	6	3	4
	ST18	4	7	5	7	7	3	4
	ST215	19	19	66	21	17	16	4
Genomes obtained in the present study								
IHUChlampneu_Mars1 (CP172581)	ST16	4	7	5	6	5	3	4
IHUChlampneu_Mars2 (CP173416)	ST16	4	7	5	6	5	3	4
IHUChlampneu_Mars3 (A0931)	ST16	4	7	5	6	5	3	4
IHUChlampneu_Mars4 (A0932)	ST16	4	7	5	6	5	3	4

116

117

APPENDIX, REFERENCES 118

- 119 1. Morel AS, Dubourg G, Prudent E, Edouard S, Gouriet F, Casalta JP, Fenollar F,
- Fournier PE, Drancourt M, Raoult D. Complementarity between targeted real-time 120
- specific PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven 121
- diagnosis of infectious diseases. Eur J Clin Microbiol Infect Dis. 2015;34(3):561-70. 122
- doi: 10.1007/s10096-014-2263-z. 123
- 2. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. 124
- Bioinformatics. 2018;34(17):i884-i890. doi: 10.1093/bioinformatics/bty560. 125
- 3. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome 126
- 127 Biol. 2019;20(1):257. doi: 10.1186/s13059-019-1891-0.

- 128 4. Lu J, Rincon N, Wood DE, Breitwieser FP, Pockrandt C, Langmead B, Salzberg SL,
- 129 Steinegger M. Metagenome analysis using the Kraken software suite. Nat Protoc.
- 130 2022;17(12):2815-2839. doi: 10.1038/s41596-022-00738-y.
- 131 5. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome
- assemblies from short and long sequencing reads. PLoS Comput Biol.
- 133 2017;13(6):e1005595. doi: 10.1371/journal.pcbi.1005595.
- 134 6. Vaser R, Šikić M. Time- and memory-efficient genome assembly with Raven. Nat

135 Comput Sci. 2021;1(5):332-336. doi: 10.1038/s43588-021-00073-4.

- 136 7. Wick RR, Holt KE. Polypolish: Short-read polishing of long-read bacterial genome
- assemblies. PLoS Comput Biol. 2022;18(1):e1009802. doi:
- 138 10.1371/journal.pcbi.1009802.
- 139 8. Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. Bakta:
- 140 rapid and standardized annotation of bacterial genomes via alignment-free sequence
- identification. Microb Genom. 2021;7(11):000685. doi: 10.1099/mgen.0.000685.
- 142 9. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush
- 143 D, Keane JA, Parkhill J. Roary: rapid large-scale prokaryote pan genome analysis.
- 144 Bioinformatics. 2015;31(22):3691-3. doi: 10.1093/bioinformatics/btv421.
- 145 10. Bayliss SC, Thorpe HA, Coyle NM, Sheppard SK, Feil EJ. PIRATE: A fast and
- scalable pangenomics toolbox for clustering diverged orthologues in bacteria.
- 147 Gigascience. 2019;8(10):giz119. doi: 10.1093/gigascience/giz119.
- 148 11. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A,
- 149 Lanfear R. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference
- 150 in the Genomic Era. Mol Biol Evol. 2020;37(5):1530-1534. doi:
- 151 10.1093/molbev/msaa015.

- 152 12. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR.
- 153 Phandango: an interactive viewer for bacterial population genomics. Bioinformatics.
- 154 2018;34(2):292-293. doi: 10.1093/bioinformatics/btx610.
- 155 13. Letunic I, Bork P. Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic
- tree display and annotation tool. Nucleic Acids Res. 2024;52(W1):W78-W82. doi:
- 157 10.1093/nar/gkae268.
- 158 14. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb
- software, the PubMLST.org website and their applications. Wellcome Open Res.
- 160 2018;3:124. doi: 10.12688/wellcomeopenres.14826.1.
- 161 15. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L,
- 162 Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. NCBI prokaryotic genome annotation
- 163 pipeline. Nucleic Acids Res. 2016;44(14):6614-24. doi: 10.1093/nar/gkw569.
- 164 16. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L,
- 165 Rolain JM. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance
- 166 genes in bacterial genomes. Antimicrob Agents Chemother. 2014;58(1):212-20. doi:
- 167 10.1128/AAC.01310-13.
- 168 17. Abat C, Chaudet H, Colson P, Rolain JM, Raoult D. Real-Time Microbiology
- 169 Laboratory Surveillance System to Detect Abnormal Events and Emerging Infections,
- 170 Marseille, France. Emerg Infect Dis. 2015;21(8):1302-10. doi:
- 171 10.3201/eid2108.141419.
- 172 18. Sayers EW, Cavanaugh M, Frisse L, Pruitt KD, Schneider VA, Underwood BA, Yankie
- L, Karsch-Mizrachi I. GenBank 2025 update. Nucleic Acids Res. 2024;gkae1114. doi:
 10.1093/nar/gkae1114.
- 175 19. McCoy AJ, Sandlin RC, Maurelli AT. In vitro and in vivo functional activity of
- 176 Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in

- peptidoglycan synthesis and fosfomycin resistance. J Bacteriol. 2003;185(4):1218-28.
- doi: 10.1128/JB.185.4.1218-1228.2003.